Neuronetics, Inc. · NASDAQ:STIM
Neuronetics — Investor Presentation (November 2024)
39 slides from Neuronetics's investor presentation, Nov 12, 2024
Slide 1: Company Presentation November 2024
Exhibit 99.2 COMPANY PRESENTATION NASDAQ: STIM November 2024 Now FDA-Cleared as an Adjunct Therapy for Ages 15 to 21!
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation contains estimates and other statistical data prepared by independent parties and by Neuronetics, Inc. (“Neuronetics” or the “Company”) relating to market size and growth and other data about the industry in which the Company operates. These estimates and
Slide 3: Forward Looking Statements (continued)
Forward Looking Statements (continued) • Greenbrook’s, Neuronetics’, and the combined company’s ability to defend against legal proceedings; • the combined company’s success in retaining or recruiting, or changes required in, its officers, key employees or directors; • the combined company’s ability
Slide 4: Presenters
n e u r o s t a r . c o m Presenters 38+ years of experience 37+ years of experience Keith Sullivan Steve Furlong President & Executive Vice President, Chief Executive Officer Chief Financial Officer & Treasurer 4
Slide 5: NeuroStar is Renewing Lives by Transforming Neurohealth
NeuroStar is Renewing Lives by Transforming Neurohealth We’re inspired every day by the opportunity to help people live more fulfilling lives 1 Market Leader in TMS Dedicated to Practice Success #1 Physician recommended Largest direct sales and with over 6.9 million treatment customer support team i
Slide 6: Over Million People Can Benefit from NeuroStar TMS
Over 29 Million People Can Benefit from NeuroStar TMS Nearly 8 million patients are poorly served by antidepressant medication • Lack of Treatment Efficacy Total Available Market • Intolerable Side Effects Adult Depression (MDD) Adolescent Depression 29.3million 1 4 21 million suffering 4.3 million
Slide 7: More Medication Isn't the Answer
More Medication Isn’t the Answer 1-4 With every new medication adult MDD patients try : And the likelihood of stopping medication The chances of feeling better go down because of side effects goes up 1. Trivedi (2006), Am J Psychiatry | 2. Rush (2006), Am J Psychiatry | 3. Fava (2006), Am J Psychiat
Slide 8: Proven, Long-Term Relief for Adult Depression
Only NeuroStar TMS has… 1 Proven, Long-Term Relief for Adult Depression Real-World Clinical Results Clinically Proven Durability 2 1 for Patients with MDD through 12 Months 83% Improvement in depression 1 symptoms 62% Symptom relief 1 (remission) . 1. Dunner DL, et al. (2014). J Clin Psychiatry. 75(
Slide 9: NeuroStar Clinical Excellence Validated by Extensive Research and Publications
NeuroStar Clinical Excellence Validated by Extensive Research and Publications Investigator Initiated Studies Largest Real-World Sample Sizes in TMS 1 Research Expands understanding of TMS and its potential clinical applications 1 6 High Impact NeuroStar Registry 65+ studies with 1,900+ patients 2-7
Slide 10: Consistent, Repeatable Treatment for Optimal Outcomes
Only NeuroStar … Delivers Consistent, Repeatable Treatment for Optimal Outcomes Contact Sensing with Real-Time Feedback Precise Coil Placement – NeuroSite™ Proprietary to NeuroStar Proprietary to NeuroStar Good Consistent Coil Contact Placement Faster Patient Setup Continuous Monitoring with Fewer S
Slide 11: Proprietary TrakStar Platform Provides Actionable Insights
Proprietary TrakStar Platform Provides Actionable Insights for NeuroStar and its Practices World’s Largest Depression Outcomes Patient Management Database 1 Registry Contributes to Future and Reporting System Indications and Publications Tools to identify more patient 188,000+ candidates (PHQ-10, Be
Slide 12: One of the Largest Issued Patent Portfolios of All TMS Companies
NeuroStar Has one of the Largest Issued Patent Portfolio of All TMS Companies… Patent Portfolio Contact Sensing MT Assist Iron Core Magnet U.S. patent U.S. patent U.S. patent • 33 US / 53 OUS Issued or allowed patents • 10 US / 6 OUS Pending patent applications …protecting our technical advantage an
Slide 13: NeuroStar: The Unrivaled TMS Solution
NeuroStar: The Unrivaled TMS Solution TouchStar FDA-cleared for iTBSTheta Burst w/Contact Sensing FDA-cleared for * * OCD Publications from 12 1 1 Depression Registration Trials FDA-cleared for Anxious Depression Practice Consultants FDA-cleared for Adolescent Depression Marketing including DTC Adve
Slide 14: Now FDA-Cleared for Adolescent Depression
TAP INTO A NEW POSSIBILITY for adolescent depression Now FDA-Cleared as a First-Line, Adjunct Treatment for Ages 15 and Older NEW: FDA-Cleared March 22, 2024
Slide 15: Treating Adolescent Depression Had Two Choices… Until Now
Treating Adolescent Depression Had Two Choices… Until Now Youth Depression is On the Rise Limited Options for Adolescents • Only 2 antidepressants are FDA-approved • Nearly 1 in 5 US adolescents experience at 1 for use in adolescents: Prozac (fluoxetine) least one major depressive episode each year
Slide 16: NeuroStar Revolutionizing Mental Health with New Adolescent Indication
As the Market Leader, NeuroStar is Revolutionizing Mental Health with New Adolescent Indication NeuroStar is the only FDA-cleared TMS st 1 and Only to Market 1 treatment for adolescent depression For adolescents, NeuroStar can be used as an st add-on treatment, without prior medication 1 Line Treatm
Slide 17: Real-World Data Demonstrates Improvement in Adolescent Depression Severity
® TrakStar Real-World Data Demonstrates Improvement in Adolescent Depression Severity 78% Improvement in depression symptoms Real-world data was collected through NeuroStar’s proprietary ® TrakStar platform, saving 48% valuable time and money Symptom relief (remission) Results analyzed from a subset
Slide 18: New Opportunity with Adolescent Psychiatrists
New Opportunity with Adolescent Psychiatrists New Customers 1,100+ Existing Customers Supported by Supported by 17 Capital Sales Representatives 45 Practice Development Managers • Expanded opportunity • Increases the value of NeuroStar system by broadening label to • 11,400+ child and 1 additional p
Slide 19: 2024 Adolescent Marketing Strategy Focused on Parents and Practices
2024 Adolescent Marketing Strategy Focused on Parents and Practices Key Messages Treats depression at the source | Non-drug, non-invasive | Proven safe and effective Outside the Practice Inside the Practice Parent Awareness & Education Practice Tools & Education Patient Advocate Collaborations
Slide 20: The Largest Direct Sales & Customer Support Team
1 The Largest Direct Sales & Customer Support Team 10 16 Experienced team 48 2 dedicated to consistent growth and practice success 18 07 14 1. Neuronetics, Inc. internal data on file 2024. 20
Slide 21: Proven Program for Ongoing Practice Success
NeuroStar Proven Program for Ongoing Practice Success Reach Source Start Train Awareness Your Patients New Patients • REIMBURSEMENT • FRONT DESK • PRACTICE BRANDING • PATIENT EMAIL • DIGITAL MARKETING CONSULTING TRAINING • WEBSITE BRANDING OUTREACH • HCP EDUCATIONAL • TRAKSTAR 1.0 • CONSULTATION • P
Slide 22: Better Me Providers Reach More Patients
NeuroStar Better Me Providers Reach the Lives of More Patients NeuroStar Better Me Program is designed to lead the industry in standards for patient care Providers are required to: The Result: 3.6x more MTs in Better Me Providers vs. 1 non-Better Me Providers 22 22
Slide 23: Better Me Providers Quickly Addressing Interested Patients
Better Me Providers are Quickly Addressing Interested Patients in Need 5x Faster 1 from potential patient interest to MT Q1 2023 Q1 2024 82 days 17 days All patient interest in Local Consumable Offices based on webform submissions from www.neurostar.com Phase 2: Feb 1, 2024 – Apr 7, 2024 vs. PY 23 1
Slide 24: NeuroStar University
NeuroStar University By September 2024, attendees to NSU increased patient treatment 62% more than accounts that did not attend.* NSU Utilization Performance Index Baseline index values are based on January 2022 utilization. Excludes new sites from Classes 2022-2024. Attended NSU +49% vs. Jan 2022 A
Slide 25: Co-Op Marketing to Build Local Consumer Awareness
Only NeuroStar Invests in Co-Op Marketing to 1 Build Local Consumer Awareness Co-Op Marketing: collaborative effort with practices to increase local patient awareness while sharing advertising costs +15% +16% treatment session utilization* in new MTs* 25
Slide 26: Available at the Largest National Mental Health Centers
NeuroStar is Available at the Largest National Mental Health Centers 26
Slide 27: Dedicated to Driving Health Policy to Ensure Broad US Reimbursement
Only NeuroStar is Dedicated to Driving Health Policy to Ensure Broad US Reimbursement NeuroStar also connects our practice partners NeuroStar TMS is covered by most commercial with financing companies to provide options for insurance carriers, all Medicare jurisdictions and many patients who have in
Slide 28: U.S. Market Leader, Opportunity to Expand Worldwide
NeuroStar is the U.S. Market Leader, Opportunity to Continue Expanding Worldwide Japan Roadmap th 1 • 11 largest healthcare spend globally nd 2 • 2 highest suicide rate after Korea • Single payor healthcare system • Shonin approval since 2017 • Exclusive distribution agreement 3 with Teijin Pharma 4
Slide 29: Leadership Team
Keith Sullivan Cory Anderson Steve Furlong Rick Grubbs Sheryl Conley Rob Cascella Glenn Muir President & CEO SVP, R&D and Clinical EVP, CFO & Treasurer SVP, National Board Chairman Accounts Megan Andrew Macan Rusty Page Lisa Rosas Sara Grubbs Keith Sullivan EVP, GC & Chief SVP, Chief Rosengarten SVP
Slide 30: Financial Overview
Financial Overview NeuroStar Advanced Therapy for Mental Health 30
Slide 31: Annual Revenue
Annual Revenue ($ in millions) Annual Revenue by Geography Annual Product Revenue (US) $80 $80 $71.0-$72.0 $71.3 $69.3 $2.0 $70 $70 $1.9 $65.2 $63.4 $1.8 $1.7 $60 $60 $55.3 $53.4 $1.9 $1.8 $50 $50 $50.9 $69.3 $40 $40 $45.1 $63.4 $41.9 $30 $30 $53.4 $20 $20 $10 $10 $16.6 $16.5 $9.8 $0 $0 2021 2022 20
Slide 32: Worldwide Quarterly Revenue
Worldwide Quarterly Revenue ($ in millions) Q3 2024 Revenue of $18.5M, a 4% increase from Q3 2023 $20.3 $19.0 -$20.0 $20 $18.2 $18.5 $17.9 $17.4 $17.6 $16.5 $16.5 $16.3 $15.5 $14.2 $15 $10 $5 $0 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Guidance
Slide 33: Results of Operations
Results of Operations ($ in thousands) 33
Slide 34: Financial Position
Financial Position ($ in thousands) 34
Slide 35: Supplemental Information
Supplemental Information NeuroStar Advanced Therapy for Mental Health 35
Slide 36: Local Consumables New MTs & Utilization
Local Consumables New MTs (New Patient Starts) & Utilization Local Consumable Monthly Utilization & New MTs Jan 2021 - Sept 2024 40,000 1,200 1,100 35,000 1,000 30,000 900 25,000 800 20,000 700 15,000 600 10,000 500 5,000 400 - 300 Utilization New MT's 36
Slide 37: U.S. NeuroStar Treatment Sessions
U.S. NeuroStar Treatment Sessions (1) = Total Treatment Session Revenue / Active Sites (Ending of Prior Quarter) 37
Slide 38: Revenue Growth Trends
Revenue Growth Trends 2021 2022 2023 Full Year YoY Full Year YoY Full Year YoY Act Growth Act Growth Act Growth Revenue Growth Drivers (NSTS) $ 35,113 20% $ 37,618 9% $ 43,936 17% NeuroStar Capital $ 9,760 -12% $ 16,575 70% $ 16,460 -1% International $ 1,865 8% $ 1,800 4% $ 2,012 12% Fixed Price Con
Slide 39: Supplemental Financial and Operating Information
Supplemental Financial and Operating Information (1) = Total U.S. Treatment Session Revenue / Active Sites (End of Prior Period) 39